People: Repros Therapeutics Inc (RPRX.W)

RPRX.W on CBOE When Trading NASDAQ Global Select Market

15.95USD
17 Apr 2014
Price Change (% chg)

$1.40 (+9.62%)
Prev Close
$14.55
Open
$15.95
Day's High
$15.95
Day's Low
$15.95
Volume
300
Avg. Vol
474
52-wk High
$29.55
52-wk Low
$13.95

Search Stocks

Summary

Name Age Since Current Position

Nola Masterson

66 2009 Independent Chairman of the Board

Joseph Podolski

65 2009 President, Chief Executive Officer, Director

Katherine Anderson

55 2011 Chief Financial Officer, Chief Accounting Officer, Secretary

Jaye Thompson

47 2013 Senior Vice President - Clinical and Regulatory

Ronald Wiehle

64 Vice President - Research & Development

Joachim Wernicke

65 2013 Chief Medical Officer

Michael Suesserman

2013 Director

Daniel Cain

67 2008 Independent Director

Saira Ramasastry

38 2013 Independent Director

Michael Wyllie

62 2011 Independent Director

Biographies

Name Description

Nola Masterson

Ms. Nola E. Masterson serves as an Independent Chairman of the Board of Repros Therapeutics Inc. She was elected a director in 2004 and became chair of the board in 2009. Since 1982, she has been the chief executive officer of Science Futures Inc., an investment and advisory firm. Ms. Masterson is currently Managing Member and General Partner of Science Futures LLC, I and II, which are venture capital funds invested in life science funds and companies. She is on the board of directors of Generex Biotechnology, Inc. (OTC BB: GNBT.OB), a Delaware corporation with headquarters in Toronto and a subsidiary in Worchester, Massachusetts. She serves on the audit committee, nominating committee and the compensation committee for Repros Therapeutics Inc. Ms. Masterson was the first biotechnology analyst on Wall Street, working with Drexel Burnham Lambert and Merrill Lynch and is a co-founder of Sequenom, Inc., a genetic analysis company located in San Diego and Hamburg, Germany. Ms. Masterson is the Chair Emeritus of the Bay Bio Institute, a 501(c) 3 part of BayBio, which promotes science education, workforce development and best practices as well as entrepreneurs in the bioeconomy. Ms. Masterson began her business career at Ames Company, a division of Bayer and spent eight years at Millipore Corporation in sales and sales management. Ms. Masterson has 33 years of experience in the life science industry. She received her Masters in Biological Sciences from George Washington University and continued Ph.D. work at the University of Florida.

Joseph Podolski

Mr. Joseph S. Podolski serves as President, Chief Executive Officer and Director of Repros Therapeutics Inc. Mr. Podolski has served as Chief Executive Officer and as a director since 1992. He joined the company in 1989 as Vice President of Operations. Previously, Mr. Podolski spent twelve years in various engineering, product development and manufacturing positions at G.D. Searle, a subsidiary of Monsanto Company. Before joining Monsanto, Mr. Podolski held positions in manufacturing, engineering, quality control and development of fine chemicals, antibiotics, pharmaceuticals and hospital products with Abbott Laboratories, Dearborn Chemical Company and Baxter Pharmaceuticals. Mr. Podolski holds a B.S. degree in chemistry and a M.S. degree in chemical engineering from the Illinois Institute of Technology.

Katherine Anderson

Ms. Katherine A. Anderson, CPA, serves as Chief Financial Officer, Chief Accounting Officer, Secretary of Repros Therapeutics Inc., Ms. Anderson originally joined the company in 2002 as an independent contractor controller and, effective October, 2009, assumed the additional position of Chief Accounting Officer. She has been Chief Financial Officer since August, 2011. Ms. Anderson is a certified public accountant with 29 years of experience in accounting and finance. Ms. Anderson earned a B.S. degree in accounting from The University of Houston.

Jaye Thompson

Dr. Jaye L. Thompson, Ph.D., has been appointed as Senior Vice President - Clinical and Regulatory of Repros Therapeutics Inc., effective March 26, 2013. She is no longer Director of Company effective Company’s 2013 Annual General Meeting. Dr. Jaye Thompson was elected a director in 2009. Ms. Thompson has more than 20 years of experience in the clinical research industry. She was most recently the Senior Vice President of Clinical Development and Regulatory Affairs with Opexa Therapeutics, Inc. Prior to joining Opexa, she was the Senior Vice President for Regulatory Affairs and Emerging Biotechnologies at inVentiv Clinical Solutions, LLC, a wholly-owned subsidiary of inVentiv Heatlh (NASDAQ: VTIV), a full-serve contract research organization. Prior to its acquisition by inVentiv in 2006, Dr. Thompson was President and Founder of SYNERGOS, Inc, a contract research organization based in The Woodlands, Texas. Dr. Thompson holds a Bachelor's degree in Applied Mathematics from Texas A&M University and an MS and a PhD in Biostatistics from the University of Texas Health Science Center in Houston. She was appointed to the Texas Emerging Technology Advisory Committee and has served on the Gulf Coast Regional Center of Innovation and Commercialization Executive Board, the MD Anderson Technology Review Committee and the BioHouston Associate Advisory Board.

Ronald Wiehle

Dr. Ronald Wiehle, Ph.D., serves as Vice President, Research and Development of Repros Therapeutics Inc. Dr. Wiehle originally joined the company in 1996 and now serves as the Vice President, Research and Development. Previously, he worked as an Assistant Biochemist at the IIT Research Institute in Chicago on animal models of human cancer. He has over 30 years of experience in biomedical sciences which includes projects involving male and female reproductive biology, cancer biology, virology and cell biology. Previously, Dr. Wiehle served as the lead scientist for all of the company's hormonally-based programs and was instrumental in the licensing of a series of SPRMs from the National Institute of Health. Dr. Wiehle received a B.S., in Chemistry, from the University of Illinois at Chicago. Dr. Wiehle earned his Ph.D. in Biochemistry from The University of Louisville School of Medicine/Health Science focusing on hormone receptors in human breast cancer. He earned a post doctoral award under a Sonderesforshungsgemeinshaft (SFG) at the Institut fuer Molekularbiologie und Tumorforshung (IMT) of the Phillips University in Marburg, Germany to study the use of recombinant retrovial vectors to transform mammalian cells. He has held faculty positions at the James Graham Brown Cancer Center/University of Louisville and the Department of Obstetrics & Gynecology at the Baylor College of Medicine. He has been awarded research grants by the NIH and local and national clinical/scientific organizations. He has authored more than 25 publications and has delivered invited lectures.

Joachim Wernicke

Joachim F. Wernicke is Chief Medical Officer of Repros Therapeutics Inc., From 2004 until his in retirement in 2012, Dr. Wernicke was part of the Global Patient Safety group at Eli Lilly and Company (“Lilly”) where he was at various times responsible for Cymbalta, Strattera, Zyprexa, Symbyax, and Effient. He was also involved in the development and approval of Strattera and Cymbalta between 1999 to 2004 and clinical development and regulatory matters related to Prozac and other central nervous system drugs between 1984 and 1990. During his career, he has also served as the VP of Clinical and Regulatory Affairs for Cyberonics, Inc. and as a consultant for various pharmaceutical, biotechnology and medical device companies. Dr. Wernicke received a Ph.D. in biochemistry from U.C.L.A. in 1974, and an M.D. from U.C. Irvine in 1979, followed by a child neurology fellowship.

Michael Suesserman

Mr. Michael Suesserman is a Director of Repros Therapeutics Inc. He is currently Managing Director, Cello Health Consulting, providing advisory services to the global life sciences industry. Mike brings over two decades of experience in launching, building, and developing pharmaceutical marketing platforms, including those for the megabrands Lipitor and Viagra. Mike's breadth of experience in commercializing pharmaceuticals spans the entire product lifecycle, including portfolio prioritization, product development, US and Global product management, life-cycle extension as well as reimbursement and market access. He spent 18 years at Pfizer, in roles of increasing responsibility. He was the US and then Global Team Leader for Lipitor, was responsible for the global urology franchise and also held the position of VP, Managed Markets Group in the US. In addition to overall commercial expertise, Mike has extensive experience in a number of therapeutic areas, particularly urology. He was responsible for the commercial development of Pfizer's Sexual Health franchise strategy, re-positioning and re-launching Viagra in the face of the global introductions of Cialis and Levitra, and creating access and formulary placement for Detrol LA in the US. Mike holds an MBA from Kelley School of Business at Indiana University and earned his Bachelor's degree in Economics from Clark University.

Daniel Cain

Mr. Daniel F. Cain serves as an Independent Director of Repros Therapeutics Inc., since 2004. He was chair of the board of directors from 2005 to 2008. Since October 1994, Mr. Cain has provided consulting services for small businesses. Since May 2000, he has also served as acting chief executive officer of Wireless Medical, Inc., a Colorado-based medical device company. From 1969 to 1994, Mr. Cain held various positions with Miles Laboratories, Inc., Hexcel Corporation, Scripps-Miles, Inc., Synbiotics Corporation and Heska Corporation. Mr. Cain has 38 years of broad business experience including 28 years with medical companies. Sixteen of these years were with three different biotech startup companies, one of which he co-founded. Mr. Cain has held a wide variety of executive level management positions including chief executive officer, president and chief financial officer. Mr. Cain earned a B.S. degree from LeTourneau College and a M.B.A. degree from Indiana University.

Saira Ramasastry

Ms. Saira Ramasastry is Independent Director of Repros Therapeutics Inc., effective March 25, 2013. Prior to joining the Board, Ms. Ramasastry was an advisor to the Company. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. From 1997 to 1998, she was a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Biosciences, Inc. and Pain Therapeutics, Inc., two publicly-held biopharmaceutical companies, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the Board of Directors of the American Liver Foundation. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as a M. Phil. in Management Studies from the University of Cambridge.

Michael Wyllie

Dr. Michael G. Wyllie, Ph.D., DSC., serves as an Independent Director of Repros Therapeutics Inc., since October 27, 2011. Dr. Wyllie has over 30 years of experience in senior management positions in the pharmaceutical industry. He is a director and founder of Global Pharma Consulting and is a graduate of the University of Aberdeen. While Director of Biology at Pfizer, he was involved in the discovery, development, regulatory filing and marketing of eight major pharmaceutical products including doxazosin (Cardura), darifenacin (Enablex) and sildenafil (Viagra). Subsequently, Dr. Wyllie has been involved in founding several start-up companies and the listing of four of these on the London Stock Market. He is founder and Chief Scientific Officer of Plethora Solutions, Plc, which has a product, PSD502, undergoing regulatory review in the EU for premature ejaculation. He is Chairman of Glycomar Ltd, the Oban-based marine biotechnology company and a member of the Clinical Trials Committee for the International Consultation in Sexual Medicine.

Basic Compensation

Search Stocks